Kornimate/medical-research-clean huggingface dataset:
ibuprofen and opioid (morphine or diamorphine) for acute pain in sickle cell disease - sickle with ibuprofen & morphine

Conditions: Sickle Cell Disease

Summary: the use of oral ibuprofen combined with opioid (morphine or diamorphine) administered through patient controlled analgesia (pca) will be clinically effective for acute pain crisis in adults with sickle cell disease (scd).

pain from vaso-occlusion in sickle cell disease (scd) is persistent, and its management continues to pose a challenge to practitioners. opioids are recommended for the treatment of severe acute scd pain, and have been used successfully within the hospital setting. non-steroidal anti-inflammatory drugs (nsaids) are recommended for acute scd pain, however there is no clear evidence for the effectiveness of oral nsaids in combination with parenteral opioids in adults with scd.data from acute pain research suggests that oral ibuprofen is one of the best nsaids for combination treatment with morphine via pca. this is a randomised controlled trail to evaluate the effectiveness of oral ibuprofen plus intravenous diamorphine or morphine via pca. the results will provide the evidence needed to recommend whether or not ibuprofen should be used in acute scd pain.

Eligibility criteria:
inclusion criteria: * adult patients with scd of any phenotype exclusion criteria: * patient has a history of allergic reaction to either diamorphine/morphine or ibuprofen * patient has contraindications to diamorphine/morphine or ibuprofen, e.g. peptic ulcer disease, non-steroidal anti-inflammatory drug (nsaid)-induced asthma * patient in a drug dependency programme * patient is on renal dialysis * stroke within the last 6 weeks * platelet count less than 50 x 10\^9/l * patient is pregnant or breastfeeding * doctor unwilling to randomise the patient for other reasons * previous participation in the trial * patient receiving drug treatment with which opioids or nsaids are likely to interact significantly * stage 1 - 5 chronic kidney disease (ref appendix 2), including urine protein: creatinine ratio of \>50 (because the ibuprofen dose is substantial it is felt that precautions should be taken to exclude those who have any signs of chronic kidney disease. one of the signs of kidney disease is "persistent proteinuria". therefore, the patient who intermittently has proteinuria(which could be due to other reasons) could still participate.) * oxygen saturation by pulse oximetry \<94% * participation in another clinical trial within the last month

Keywords: sickle cell disease pain ibuprofen morphine diamorphine patient controlled analgesia
ktrsensor scotland study: an observational study into predictors and diagnosis of kidney transplant rejection

Conditions: Kidney Transplant; Kidney Disease, Chronic

Summary: an observational study capturing real world transplant patients in the post-operative setting aiming to further determine the utility of biomarkers to improve outcomes.

a prospective longitudinal observational study capturing patients receiving kidney transplants in scotland. the primary objective is to assess whether there are clinical biomarkers present in the urine that determine the outcome of kidney transplants and predict early graft rejection.

Eligibility criteria:
any patient within a scottish transplant centre who has undergone renal transplant (+/- pancreas/islet) and is due to attend routine follow-up appointments at the index centre. exclusion criteria: * no previous kidney transplant * patient attending follow-up at a peripheral site * unable to provide urine samples across the study duration
relationship between circulating tumor stem cells and the clinical pathology

Conditions: Cancer Stem Cells; Postoperative Recurrence and Metastasis; Hepatocellular Carcinoma

Summary: the aim of this study is to establish a platform of detecting and sorting circulating tumor stem cells from peripheral blood in hcc patients; to investigate the relationship between circulating tumor stem cells and their effects on postoperative recurrence and metastasis, in order to provide a new therapeutic target for hepatocellular carcinoma treatment.


Eligibility criteria:
inclusion criteria: 1. male or female patients \> 18 years and \<=70 years of age; 2. no dysfunction in major organs; blood routine, kidney function, cardiac function and lung function are basically normal. 3. patients who can understand this trial and have signed information consent exclusion criteria: 1. reject to attend； 2. impossible to come to our hospital for physical examination regularly; 3. patients with other diseases which may affect the treatment mentioned

Keywords: cancer stem cells
a clinical trial comparing the omni surgical system to standard medical treatment in patients with primary open angle glaucoma

Conditions: Primary Open Angle Glaucoma

Summary: a randomized clinical trial of ab interno canaloplasty and trabeculotomy with the omni® surgical system compared to standard medical treatment as a standalone procedure in patients with primary open angle glaucoma (evolve)

this prospective, multicenter, post-market clinical trial will evaluate the safety and effectiveness of canaloplasty and trabeculotomy using the oss as a standalone procedure in patients with poag.

Eligibility criteria:
inclusion criteria: 1. male or female subjects, 45 years or older. 2. history of uncomplicated cataract surgery and posterior chamber intraocular lens (iol) implantation without compromise to the lens capsule, zonular dehiscence/rupture or vitreous prolapse, 6 months or more prior to baseline visit (pseudophakic subjects), or, phakic and no anticipated need for cataract surgery over the study duration. 3. under treatment with a topical prostaglandin f2 analog (e.g. latanoprost, travoprost, bimatoprost, tafluprost) either as monotherapy or in combination with one (1) adjunctive medication for a minimum of 6 weeks prior to the screening visit. 4. intraocular pressure (iop) at the screening visit of \>18 and not exceeding 36 mmhg. 5. diagnosed with primary open angle glaucoma (poag). exclusion criteria: 1. any of the following prior ocular procedures: * laser trabeculoplasty ≤180 days prior to baseline * durysta ≤12 months prior to baseline unless failure is documented and topical medication including a prostaglandin analog is in use as per inclusion criterion # 3. * implanted with istent (all types), cypass, xen, express, glaucoma draining device/valve, or hydrus device; or * prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy, endoscopic cyclophotocoagulation (ecp), cyclophotocoagulation or cpc (g probe) * retinal laser procedure ≤3 months prior to baseline 2. concurrent iop-lowering procedure other than the study procedure (oss) (e.g. ecp, cpc,etc.) 3. forms of glaucoma other than poag including but not limited to: pigmentary, pseudoexfoliative, acute angle closure, normal tension, pre-perimetric, traumatic, congenital, malignant, uveitic, neovascular or severe glaucoma as documented in subject's medical record. 4. women of childbearing potential if they are currently pregnant or intend to become pregnant during the study period; are breast-feeding; or are not in agreement to use adequate birth control methods to prevent pregnancy throughout the study
effects of movement retraining on knee loading in individuals with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: this study investigates how well individuals with knee osteoarthritis can learn to alter their calf muscle activation using haptic biofeedback while walking and evaluates how these changes affect knee loading. prior research has utilized musculoskeletal simulations to determine that reducing the activation of one of the calf muscles, the gastrocnemius, can have a large impact on reducing knee loading. however, this has not been tested in individuals with knee osteoarthritis. in this study, participants will be trained to alter the activation of their gastrocnemius muscle, by receiving haptic feedback after each step. the feedback will indicate how the participant changed their muscle activation relative to baseline. participants will train for up to three sessions, with 30 minutes of walking with feedback in each session. if a participant can learn to adjust their muscle activation in the first training session, they will be able to complete the second training session. an exploratory third session may be conducted to investigate changes in knee loading while using the new walking strategy during over-ground walking. the movement data collected during the training sessions will be used as inputs to computer simulations of the musculoskeletal system to determine if walking with the new muscle activation strategy reduces knee loading.


Eligibility criteria:
inclusion criteria: * medial and/or lateral compartment knee osteoarthritis * diagnosed with knee osteoarthritis of at least six months duration * ambulatory without aids * able to walk for at least 60 minutes * typical pain rating less than or equal to 4 on scale of 0-10 * able to reduce gastrocnemius muscle activation by 10% from baseline exclusion criteria: * history of symptomatic arthritis in lower limb joints other than the knees * replacement of any lower extremity joint * symptoms originating from the patellofemoral joint * body mass index equal to or greater than 35 * nerve or muscle disease associated with walking difficulty * history of rheumatoid arthritis, gout, or autoimmune disease * history of lower limb fracture or surgery requiring hospitalization * pregnant * severe knee malalignment, defined as a hip-knee-ankle angle of more than 5 degrees from neutral * recurrent giving way of the knee
reduction of nosocomial vancomycin -resistant enterococci (vre) colonization and infection by active surveillance and intervention of infection control

Conditions: Infection

Summary: vancomycin -resistant enterococci(vre) has emerged as one of the most common nosocomial pathogen of health-care associated infection since 1988. although the new antimicrobial agents such as tigecycline , daptomycin, linezolid have clinically effectiveness for the treatment of vre, but there was not appropriate drugs for eradicating the colonization of vre. so the active surveillance and strict contact precaution are the best methods for vre colonization and transmission. this is a one year study program, we select a unit as the study site. first month (january) is the prepare period. therefore , we collect 3 months (from february to april) baseline data, then interrupted one month(may) for the health care worker's infection control education. then the intervention period are three months (from june to august), and the last four months(from september to december) are the analysis and evaluation period. in the baseline period, we only do the patient's active surveillance and environmental culture. in the intervention period, beside the patient's active surveillance and environmental culture, we add contact precaution as the infection control method. if patient has vre infection, we prescribe appropriate antibiotic therapy until the culture result proved no growth of vre. the aim of this study is to compare and analyze these two period (baseline period and intervention period) for understanding the transmission, risk factors and carriage rate of vre, as the important guidelines for the vre infection control in the future.


Eligibility criteria:
inclusion criteria: * all patients admitted to rcc unit exclusion criteria: * if the patients or family refused the exam of anal swab .

Keywords: for the active surveillance of vre colinization and infection
opioid free versus opioid balanced anesthesia in ophthalmic surgery

Conditions: Anesthesia and Analgesia; Anesthesia, Endotracheal

Summary: anesthesia without the use of opioid (opioid free anesthesia) is an alternative to conventional opioid balanced anesthesia, with less post operative nausea and vomiting, and comparable analgesia. this study aim to compare the effect of opioid free versus opioid balanced anesthesia in ophthalmology surgery


Eligibility criteria:
inclusion criteria: * physical status of asa 1-2 * undergo elective ophthalmology surgery under general anesthesia with laryngeal mask insertion * bmi 17.5-34.9 exclusion criteria: * allergy to study drugs * baseline heart rate \< 70 beat per minute or systolic blood pressure \< 100 mmhg * will undergo regional block * operation lasting for \> 4 hours or \< 90 minutes * consumes opioid routinely prior to operation

Keywords: opioid free anesthesia ocular surgery ophthalmology surgery dexmedetomidine post operative nausea and vomiting
prognostic biomarkers in samples from young patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. purpose: this research study is studying prognostic biomarkers in cell samples from young patients with acute myeloid leukemia.

objectives: primary * to determine the percentage of primary acute myeloid leukemia (aml) samples with increased stat3 signaling pathway activity. * to evaluate the presence of constitutive stat3 activation and the sensitivity of stat3 activation to low- and high-doses of cytokines. * to evaluate the expression levels of stat3 protein and the upstream and downstream regulators of stat3 activation. secondary * to classify samples according to a stat3 activation pattern and correlate this result with event-free survival (efs) and overall survival (os). outline: cryopreserved aml specimens are analyzed for pstat3 and pstat5 levels, response to cytokine levels, and expression level of proteins known to influence stat activity by flow cytometry and western blot assays. results are also compared with prognostic variables determined in ccg-291 study, including age, race, wbc, and cytogenetic risks.

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia (aml) * cryopreserved aml specimens patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: childhood acute myeloid leukemia/other myeloid malignancies
using 18f- fdg,18f-dopa and 68ga-dotatate pet/ct in detection and evaluation of response in patients with net undergoing prrt

Conditions: Neuroendocrine Tumors

Summary: the investigators will follow up after patients with neuroendocrine tumors who undergo prrt treatment and evaluate the response for treatment using pet/ct with different tracers

patients with suspected or biopsy proven net will undergo imaging using a combination of 18f- fdg , 18f-dopa and 68ga-dotatate pet/ct before the stat of prrt . after two cycles of treatment another two pet/ct are done using 18f- fdg and 18f-dopa and about 6-8 weeks from last treatment the patient will undergo pet/ct using 18f-dopa .

Eligibility criteria:
inclusion criteria: * patient with neuroendocrine tumor * eligible for prrt exclusion criteria: * younger than 18 years old * pregnancy

Keywords: peptide receptor radionuclide treatment
effectiveness and cost-effectiveness of a telemonitoring program for diabetic people at home

Conditions: Type 2 Diabetes

Summary: severity of diabetes is related to the development of disabling and costly complications (12.9 billion euros in 2007). the french high health authority recommends a therapeutic education on lifestyle and dietary rules in first-line treatment of type 2 diabetes mellitus. despite these recommendations, patients often have difficulties to implement dietary recommendations every day. the objective of educ@dom is to help people with diabetes to improve lifestyle and equilibrium of glycaemia in order to avoid or delay chronic complications of diabetes. our main goal is to assess effectiveness of our telemonitoring program in type 2 patients' care compared to a usual care of diabetes, on the glycaemia of the patients. it is expected that our program leads to a better monitoring of health status, a greater adherence to medical and non-medical prescriptions, an empowerment of the patient, and as a consequence, a more efficient health care consumption.


Eligibility criteria:
inclusion criteria: * patient with type 2 diabetes * older than 18 years * with an insulin treatment or not * having a glycemic impairment characterized by 6.5% \<hba1c ≤10 * having an active internet connection at home. * accepting the terms of training, loan and use of the device * benefiting from social protection system * having given his/her free and informed consent and signed the consent exclusion criteria: * serious illness recently (\<3 months) or decompensated may influence glycemic control of the patient permanently according to the judgment of the physician in charge of monitoring * retinal state that does not allow optimization in equilibrium of glycaemia * known severe renal impairment defined by creatinine clearance \<30ml/min * known hemoglobinopathy * visual or intellectual resulting inability to use the remote monitoring tool according to the judgment of the physician in charge of monitoring * inability to understand all or part of the software information according to the judgment of the physician in charge of monitoring * subject to disabled * person with severe behavioral disorders (anorexia, bulimia, ...) according to the judgment of the physician in charge of monitoring * person who had, or in preparation for bariatric surgery (software nutrition education are not suitable for this type of care.) * person with a medical device implanted electronic pacemakers and defibrillators with cardiac (possibility of interference with the impedance) * another person involved in research including a period of ongoing exclusion to inclusion, * a person under legal protection * subject living in institutions * desire for pregnancy, pregnancy or breastfeeding

Keywords: telemedicine telemonitoring education nutrition food behaviour weight physical activity glycaemia self-monitoring blood glucose
exenatide and impaired hypoglycaemic awareness in type 1 diabetes

Conditions: Diabetes Mellitus, Type 1; Hypoglycemia

Summary: approximately 25% of patients with type 1 diabetes have lost the capacity to timely detect hypoglycaemia, a condition referred to as impaired hypoglycaemic awareness (iha) that causes a six-fold higher risk of severe, potentially hazardous, hypoglycaemia. iha is usually the end-result of a process of habituation to recurrent hypoglycemia that is potentially reversible. treatment with glucagon-like peptide (glp)-1 receptor agonists (1ras) in addition to insulin therapy may decrease the incidence of hypoglycaemia in patients with type 1 diabetes. this study will test the hypothesis that treatment with the glp-1ra, exenatide, added to basal-bolus insulin therapy will improve awareness of hypoglycaemia in patients with type 1 diabetes and iha. in a randomized doubleblind placebo-controlled cross-over trial, patients will be treated for 6 weeks with exenatide (or placebo), after which hypoglycemic symptoms and counterregulatory hormone responses will be examined during a hyperinsulinemic hypoglycemic glucose clamp study.


Eligibility criteria:
inclusion criteria: * type 1 diabetes, disease duration \>1 year * age \>18 years, \<70 years * insulin treatment according to basal-bolus insulin regimen (injections or insulin pump) * impaired hypoglycaemic awareness as assessed by a score of 3 or more on the modified dutch translation of the clarke questionnaire * glycated haemoglobin (hba1c) ≥42 mmol/mol (6%) and ≤75 mmol/mol (9.0%) * ability to provide informed consent exclusion criteria: * treatment with incretin-based therapy * known intolerance to glp-1ras (including allergy) * treatment with glucose-modifying or immune-modifying agents, e.g. prednisolon * recent history of myocardial infarction or stroke (past year) or laser coagulation for proliferative retinopathy (past 6 months) * proliferative retinopathy * symptomatic diabetic neuropathy * diabetic nephropathy as reflected by albumin-creatinin ratio \>30 mmol/mg or estimated glomerular filtration rate (egfr) \<60 ml/min/1.73 m2 * known heart failure * history of pancreatitis (acute or chronic) or pancreatic cancer * body-mass index \>40 kg/m2 * use of premixed insulin or of long-acting insulin alone * total daily insulin dose requirements \<20 units unless on pump treatment * pregnancy or unwillingness to undertake measures for birth control

Keywords: glucagon-like peptide 1 impaired hypoglycemic awareness
a trial of the safety, tolerability, and pharmacodynamics of cvl-871 in subjects with dementia-related apathy

Conditions: Apathy in Dementia

Summary: the purpose of this study is to determine whether cvl-871 is safe and tolerable in patients with dementia-related apathy and if cvl-871 shows changes in clinical measurements of apathy.


Eligibility criteria:
inclusion criteria: * meets diagnostic criteria for apathy in neurocognitive disorders * clinically significant apathy * mild to moderate dementia (ad, ftd, vad, or dlb) exclusion criteria: * other significant psychiatric disorder(s) * other neurological disorders (other than ad, ftd, vad, or dlb)

Keywords: dementia apathy
hair cortisol as marker of chronic stress in preterm and term fathers - fathair-study

Conditions: Stress, Psychological; Father-Child Relations; Premature Birth

Summary: the goal of this observational study is to compare the paternal hair cortisol as a marker for chronic stress in prematurely born children to maturely born children. the main questions it aims to answer are: * how differ the cortisol level between groups? * how change the cortisol level over time? * are there secondary outcomes associated to the cortisol level of fathers? participants will give a hair sample to analyse the cortisol level and fill out questionnaires at three time points. at six months of the infant's age, the investigators will also measure the paternal sensitivity.

for expectant parents, the birth of a child is often a stressful situation. in the case of a premature birth, the psychological stress is usually increased because the parents frequently could not prepare for the birth. therefore, the researcher would like to investigate this stress of fathers of newborn children. for this purpose, the stress hormone cortisol in the fathers' hair will be analysed and questionnaires on the fathers' mental health will be collected. subsequently, the differences between fathers of prematurely born and of maturely born children will be compared. the investigators will do the analyses at three time points: the first time point will be at the first week after birth, the second three months and the third six months after birth. at six months of the infant's age, additionally the paternal sensitivity will be measured. the compared groups will differ with respect to gestational age: group 1 includes preterm infants with a gestational age below 32 weeks and a birth weight \<1500 grams (very low birthweight infants), group 2 preterm infants with a gestational age between 32 0/7 to 36 6/7 (moderate and late preterm infants) and group 3 consists of mature infants (over 37 weeks gestational age).

Eligibility criteria:
inclusion criteria: * premature or mature infant (22 0/7 to 42 0/7 weeks of gestation) * for mature infants (37 0/7 to 42 0/7 weeks of gestation) undisturbed neonatal period * no severe malformations or genetic diseases of the newborn child * sufficient knowledge of german of the father * written consent of the custodial parents exclusion criteria: * adoptive or foster paternity * hair length below 3 cm at the posterior vertex region of the back of the father's head * endocrine disorders, especially of the adrenocortical system (e.g. cushing syndrome, adrenal insufficiency) * taking steroidal medications or other drugs that affect the activity of the hypothalamic-pituitary-adrenocortical system * paternal psychological or severe physical illness